{"title":"迈向新的β来源照顾deldiabete -cellule 1型糖尿病;","authors":"V. Zamarian, Silvia Pellegrini, Valeria Sordi","doi":"10.30682/ildia2202h","DOIUrl":null,"url":null,"abstract":"Pluripotent stem cells are the best candidates for a renewable and infinite source of β-cells suitable for a future application in cell ther-apy for type 1 diabetes. Obtaining a cellular product that is safe and functional is becoming urgent, as the first clinical trials using stem cell-derived β cells are ongoing. This review summarizes the current strategies applied in the field of stem cell derived-β cells to improve in vitro differentiation and to solve the problems of tumorigenicity and immune rejection for a future stem cell based cell therapy.","PeriodicalId":119243,"journal":{"name":"Il Diabete","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Verso una nuova fonte di β-cellule per la cura del\\ndiabete mellito di tipo 1\",\"authors\":\"V. Zamarian, Silvia Pellegrini, Valeria Sordi\",\"doi\":\"10.30682/ildia2202h\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pluripotent stem cells are the best candidates for a renewable and infinite source of β-cells suitable for a future application in cell ther-apy for type 1 diabetes. Obtaining a cellular product that is safe and functional is becoming urgent, as the first clinical trials using stem cell-derived β cells are ongoing. This review summarizes the current strategies applied in the field of stem cell derived-β cells to improve in vitro differentiation and to solve the problems of tumorigenicity and immune rejection for a future stem cell based cell therapy.\",\"PeriodicalId\":119243,\"journal\":{\"name\":\"Il Diabete\",\"volume\":\"23 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Il Diabete\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30682/ildia2202h\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Il Diabete","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30682/ildia2202h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Verso una nuova fonte di β-cellule per la cura del
diabete mellito di tipo 1
Pluripotent stem cells are the best candidates for a renewable and infinite source of β-cells suitable for a future application in cell ther-apy for type 1 diabetes. Obtaining a cellular product that is safe and functional is becoming urgent, as the first clinical trials using stem cell-derived β cells are ongoing. This review summarizes the current strategies applied in the field of stem cell derived-β cells to improve in vitro differentiation and to solve the problems of tumorigenicity and immune rejection for a future stem cell based cell therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
